The first HDAC inhibitor approved by the FDA, in 2006, was Vorinostat (SAHA) for the treatment of cutaneous T-cell lymphoma (CTCL).15 The gene discussed is HDAC9; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.